Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

References

Page 1

	Year	Citations
Regression Models and Life-Tables D. R. Cox Journal of the Royal Statistical Society Series B (Statistical Methodology) Regression ModelsReliability EngineeringConditional LikelihoodEngineeringLife Prediction	1972	38.8K
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin, New England Journal of Medicine	2015	11.6K
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, New England Journal of Medicine	2017	7.5K
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, New England Journal of Medicine	2016	7K
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death Sreenivasa Rao Kondapally Seshasai, Stephen Kaptoge, Alexander Thompson, New England Journal of Medicine	2011	2.7K
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Marc A. Pfeffer, Brian Claggett, Rafael Díaz, New England Journal of Medicine	2015	2.3K
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, New England Journal of Medicine	2017	2.1K
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes Aidin Rawshani, Araz Rawshani, Stefan Franzén, New England Journal of Medicine	2017	1.3K
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored John J.V. McMurray, Hertzel C. Gerstein, Rury R. Holman, The Lancet Diabetes & Endocrinology Diabetes ManagementHeart FailureCardiovascular DiseaseDiabetesCardiac Care	2014	312
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Tina Vilsbøll, Stephen C. Bain, Lawrence A. Leiter, Diabetes Obesity and Metabolism	2017	264

Page 1